Cardiovascular effects of omeprazole and famotidine.
In a randomized, placebo-controlled, double-blind, crossover comparison, 12 patients with congestive heart failure (New York Heart Association class II) and dyspeptic complaints were treated orally for 1 week each with placebo, 40 mg omeprazole daily, and 40 mg famotidine daily. Non-invasive haemodynamic measurements were taken on the last day of treatment. Although omeprazole did not alter cardiac performance in impedance cardiography and mechanocardiography, the administration of famotidine led to a significant fall in stroke volume and cardiac output as compared with placebo (both p less than 0.05). Thus, omeprazole did not exert any relevant cardiovascular effects, in contrast to the H2-receptor antagonist famotidine.
Halabi
A
A
First Medical Clinic, Christian Albrechts University, Kiel, Germany.
Kirch
W
W
D000368:Aged; D002302:Cardiac Output / Q000187:drug effects; D004311:Double-Blind Method; D004415:Dyspepsia / Q000188:drug therapy; D015738:Famotidine / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000503:physiopathology*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000494:pharmacology / Q000627:therapeutic use*; D013318:Stroke Volume / Q000187:drug effects
D015738:Famotidine; D009853:Omeprazole